FDA admits mistake in approving knee device

Oct 14, 2010

(AP) -- The Food and Drug Administration says it made a mistake in approving a controversial knee implant against the advice of its scientific reviewers.

The unprecedented announcement comes a year after the agency first acknowledged that its decision to approve ReGen Biologics' Menaflex implant was influenced by outside pressure, including lobbying by four lawmakers from the company's home state of New Jersey.

The 2008 decision to approve the devise was made despite protests by FDA scientists that Menaflex - which reinforces damaged knee tissue - provides little, if any, benefit to patients.

The FDA says it is taking steps to revoke Menaflex's approval, although it also plans to meet with the company to discuss what data would be needed to prove the device is actually safe and effective.

Explore further: New treatment approved for rare form of hemophilia

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Device approval exposes political pressure on FDA

Sep 25, 2009

(AP) -- The Food and Drug Administration has taken the unprecedented step of acknowledging that it buckled to "extreme" pressure from Capitol Hill in its approval of a knee repair device last year. While FDA officials call ...

FDA moves toward tighter medical device oversight

Aug 04, 2010

(AP) -- Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed ...

FDA medical device approvals get external review

Sep 23, 2009

(AP) -- The Food and Drug Administration is asking the government's top medical advisers to review its system for approving certain types of medical devices, which has been criticized by safety advocates and government watchdogs.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

CarolinaScotsman
not rated yet Oct 14, 2010
FDA caving to political pressure, nothing new. FDA admitting it, world shaking.